Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$13.96 - $19.67 $169,446 - $238,754
-12,138 Reduced 6.71%
168,795 $2.43 Million
Q2 2022

Aug 15, 2022

SELL
$8.22 - $15.13 $335,713 - $617,924
-40,841 Reduced 18.42%
180,933 $2.74 Million
Q1 2022

May 16, 2022

SELL
$6.55 - $17.42 $1.07 Million - $2.85 Million
-163,666 Reduced 42.46%
221,774 $2.64 Million
Q4 2021

Feb 14, 2022

BUY
$15.51 - $29.31 $505,641 - $955,535
32,601 Added 9.24%
385,440 $6.25 Million
Q3 2021

Nov 12, 2021

BUY
$27.47 - $37.31 $901,208 - $1.22 Million
32,807 Added 10.25%
352,839 $10.1 Million
Q2 2021

Aug 13, 2021

BUY
$25.45 - $37.64 $3.53 Million - $5.21 Million
138,540 Added 76.33%
320,032 $10.8 Million
Q1 2021

May 17, 2021

BUY
$29.16 - $51.96 $5.29 Million - $9.43 Million
181,492 New
181,492 $5.49 Million

Others Institutions Holding YMAB

About Y-mAbs Therapeutics, Inc.


  • Ticker YMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,719,500
  • Market Cap $356M
  • Description
  • Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...
More about YMAB
Track This Portfolio

Track Lombard Odier Asset Management (Switzerland) Sa Portfolio

Follow Lombard Odier Asset Management (Switzerland) Sa and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lombard Odier Asset Management (Switzerland) Sa, based on Form 13F filings with the SEC.

News

Stay updated on Lombard Odier Asset Management (Switzerland) Sa with notifications on news.